Yayınlar & Eserler

Yayın Ağı
Makaleler 37
Tümü (37)
SCI-E, SSCI, AHCI (30)
SCI-E, SSCI, AHCI, ESCI (34)
ESCI (4)
Scopus (34)
TRDizin (5)
Diğer Yayınlar (1)

1. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors

Şahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.
Journal of Oncological Science , cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin) Creative Commons License identifier

2. Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid

TUNCEL M., KÖKSAL D., DİKMEN E., Şimşir C., Pala A., AKTAŞ B. Y., et al.
European Journal of Nuclear Medicine and Molecular Imaging , 2026 (SCI-Expanded, Scopus) identifier identifier

3. Biopsychosocial model-based exercise improves muscle strength, proprioception, pain, function, and quality of life in rheumatoid arthritis patients with knee involvement: a randomized controlled clinical tiral

Akgoz A., Yakut Y., Tufekci O., AKTAŞ B. Y., Sari E. O., Barlak A., et al.
RHEUMATOLOGY INTERNATIONAL , cilt.45, sa.9, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

4. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.
BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

5. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.
Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

6. Vaccination attitudes and practices of physicians and nurses in adult oncology settings

Ozdemir-Ayduran N., AKTAŞ B. Y., KILIÇKAP S., EKİNCİOĞLU A.
JOURNAL OF RESEARCH IN PHARMACY , cilt.28, sa.3, ss.612-620, 2024 (ESCI, Scopus, TRDizin) Creative Commons License identifier identifier identifier

7. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.
Journal of Cancer Research and Clinical Oncology , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

8. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology , cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

9. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

10. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

11. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., et al.
SOUTH ASIAN JOURNAL OF CANCER , cilt.11, ss.287-292, 2022 (ESCI, Scopus) Creative Commons License identifier identifier identifier

12. Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics

Ozer O., NEMUTLU E., REÇBER T., Eylem C. C., AKTAŞ B. Y., KIR S., et al.
EUROPEAN JOURNAL OF MASS SPECTROMETRY , cilt.28, sa.1-2, ss.56-64, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

13. Pazopanib-induced chylothorax in a patient with renal cell carcinoma

KÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D.
ANTI-CANCER DRUGS , cilt.33, sa.1, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

14. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

15. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY , cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

16. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

17. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

18. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?

Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.
CUREUS , cilt.13, sa.6, 2021 (ESCI) Creative Commons License identifier identifier

19. The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).

Bilgetekin I., Dogan M., Karacin C., Basal F. B., Esin E., Ucar G., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

20. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis

Akbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., et al.
LABORATORY INVESTIGATION , cilt.101, ss.796-797, 2021 (SCI-Expanded, Scopus) identifier

21. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis

Akbulut D., Yuksel S., Kircali E., AKTAŞ B. Y., Kaygusuz G., Saglam A., et al.
MODERN PATHOLOGY , cilt.34, ss.796-797, 2021 (SCI-Expanded, Scopus) identifier

22. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

23. Cancer incidence in Behcet's disease

GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.
IRISH JOURNAL OF MEDICAL SCIENCE , cilt.189, sa.4, ss.1209-1214, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER , cilt.19, sa.3, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

25. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus) identifier

26. Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus) identifier

27. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications

GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.
FUTURE ONCOLOGY , cilt.16, sa.9, ss.497-506, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

28. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

29. Vitamin D Supplementation and Prevention of Type 2 Diabetes

AKTAŞ B. Y., Aktas O. O.
NEW ENGLAND JOURNAL OF MEDICINE , cilt.381, sa.18, ss.1784, 2019 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

30. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.
EXPERT REVIEW OF ANTICANCER THERAPY , cilt.19, sa.7, ss.589-601, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

31. Successful Treatment of Amyloid A-Type Amyloidosis Due to Behcet Disease With Tocilizumab

İLBAY A., ERDEN A., SARI A., ARMAĞAN B., AKTAŞ B. Y., BÖLEK E. Ç., et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY , cilt.25, sa.4, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

32. Evaluation of cancer risk in patients with periodontal diseases

Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.3, ss.826-831, 2019 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier identifier

33. Mortality Facts in Internal Medicine Wards: A Descriptive Study froma University Hospital

ÇALIK BAŞARAN N., AKTAŞ B. Y., ŞENER Y. Z., CEYLAN S., YEKEDÜZ E., BAŞPINAR B., et al.
Acta Medica , cilt.49, sa.4, ss.6-13, 2018 (TRDizin) Creative Commons License

34. Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa).

SUNGUR T., ASLIM B., Karaaslan C., AKTAS B. Y.
Anaerobe , cilt.47, ss.137-144, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

35. Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center

ŞENER Y. Z., AKTAŞ B. Y., Erden A., KILIÇ L., Armagan B., İNKAYA A. Ç., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus) identifier

36. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results

KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus) identifier

37. Kliniko-patolojik olgu tart›flmas›:Sistemik lupus eritematosus

AKTAŞ B. Y., KALYONCU U., İNKAYA A. Ç., TUNCER M. A., ARSAVA E. M., KARLI OĞUZ H. K.
RAED dergisi , cilt.6, sa.1, ss.36-41, 2014 (Hakemli Dergi)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 10

1. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, cilt.33, (Özet Bildiri) identifier

2. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

3. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) identifier

4. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

5. Metastatic Choroidal Melanoma: Single Center Experience

AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.
2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, ss.1-48, (Tam Metin Bildiri)

6. Evaluation of cancer risk in patients with periodontal diseases.

GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.
2018 ASCO Annual Meeting, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, cilt.36, ss.13571, (Özet Bildiri) Creative Commons License Sürdürülebilir Kalkınma identifier

7. TÜRKIYE’DE METASTATIK MEME KANSERINDE HER2 HEDEFLITEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLILIKVERILERI

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., et al.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Türkiye, 21 - 24 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

8. Retrospective Investigation of sepsis related inpatient mortality

AKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., öztürk aktaş ö., ÖZIŞIK L., et al.
ECIM, 31 Ağustos - 02 Eylül 2017, (Özet Bildiri)

9. Retrospektive investigation of sepsis related inpatient mortality

AKTAŞ B. Y., ÇALIK BAŞARAN N., ŞENER Y. Z., BÖLEK E. Ç., ÖZTÜRK AKTAŞ ö., ÖZIŞIK L., et al.
16th European Congress of Internal Medicine, 31 Ağustos - 02 Eylül 2017, (Özet Bildiri)

10. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program

AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.
7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma
Kitaplar 1

1. PATOFİZYOLOJİNİN TEMELLERİ

DURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.
PALME YAYINCILIK, 2017
Metrikler

Yayın

48

Yayın (WoS)

39

Yayın (Scopus)

34

Atıf (WoS)

96

H-İndeks (WoS)

6

Atıf (Scopus)

128

H-İndeks (Scopus)

6

Atıf (Scholar)

2

H-İndeks (Scholar)

1

Açık Erişim

9
BM Sürdürülebilir Kalkınma Amaçları